| Literature DB >> 23687337 |
Nicole Longoni1, Manuela Sarti, Domenico Albino, Gianluca Civenni, Anastasia Malek, Erica Ortelli, Sandra Pinton, Maurizia Mello-Grand, Paola Ostano, Gioacchino D'Ambrosio, Fausto Sessa, Ramon Garcia-Escudero, George N Thalmann, Giovanna Chiorino, Carlo V Catapano, Giuseppina M Carbone.
Abstract
Chromosomal translocations leading to deregulated expression of ETS transcription factors are frequent in prostate tumors. Here, we report a novel mechanism leading to oncogenic activation of the ETS factor ESE1/ELF3 in prostate tumors. ESE1/ELF3 was overexpressed in human primary and metastatic tumors. It mediated transforming phenotypes in vitro and in vivo and induced an inflammatory transcriptome with changes in relevant oncogenic pathways. ESE1/ELF3 was induced by interleukin (IL)-1β through NF-κB and was a crucial mediator of the phenotypic and transcriptional changes induced by IL-1β in prostate cancer cells. This linkage was mediated by interaction of ESE1/ELF3 with the NF-κB subunits p65 and p50, acting by enhancing their nuclear translocation and transcriptional activity and by inducing p50 transcription. Supporting these findings, gene expression profiling revealed an enrichment of NF-κB effector functions in prostate cancer cells or tumors expressing high levels of ESE1/ELF3. We observed concordant upregulation of ESE1/ELF3 and NF-κB in human prostate tumors that was associated with adverse prognosis. Collectively, our results define an important new mechanistic link between inflammatory signaling and the progression of prostate cancer. ©2013 AACR.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23687337 DOI: 10.1158/0008-5472.CAN-12-4537
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701